Digoxin toxicity and DigiFab

Overview

• Digoxin has one of the narrowest therapeutic indices in clinical medicine.
• The gap between a therapeutic level and a lethal one is small, and toxicity is compounded by interactions that are ubiquitous in ICU patients, renal failure, electrolyte disturbances, polypharmacy.
• Understanding the pharmacology explains every clinical feature of toxicity, and DigiFab is among the most targeted antidotes in toxicology: knowing when and how to dose it is examinable and life-saving.

Pharmacology Relevant to Toxicity

Mechanism of Action

• Digoxin inhibits the Na⁺/K⁺-ATPase pump on myocardial cell membranes.
• This pump normally extrudes 3 Na⁺ in exchange for 2 K⁺.

Its inhibition causes:

• ↑ intracellular Na⁺ → saturates the Na⁺/Ca²⁺ exchanger (NCX) → ↑ intracellular Ca²⁺ → positive inotropy
• ↑ vagal tone via sensitisation of cardiac baroreceptors and direct vagomimetic effect → ↓ sinus rate, ↑ AV nodal refractoriness → negative chronotropy and dromotropy

At toxic concentrations, uncontrolled intracellular Ca²⁺ overload generates delayed afterdepolarisations (DADs) → triggered automaticity → ventricular ectopy, bidirectional VT, VF.

Key Pharmacokinetic Parameters

Pitfall: A digoxin level drawn <6 hours after an acute oral ingestion does not reflect tissue distribution, it will be falsely elevated. Repeat at 6 hours minimum.

Toxicity Mechanisms

Electrophysiological Consequences

• The combination of increased automaticity (Ca²⁺ overload, DADs) and increased vagal tone (↑ AV block) creates a paradoxical situation: ectopic pacemakers fire while the AV node conducts poorly.
• This explains why almost any arrhythmia can occur in digoxin toxicity.

Classic arrhythmias:

• AV block (1st, 2nd, particularly Mobitz I/Wenckebach, 3rd degree)
• Paroxysmal atrial tachycardia with AV block ("PAT with block"), classically digoxin-toxic
• Bidirectional VT: alternating QRS axis beat-to-beat; pathognomonic of digoxin (or occasionally aconite) toxicity
• Junctional rhythms: accelerated junctional tachycardia common
• Sinus bradycardia / sinus arrest
• VT / VF: late, life-threatening, triggered by Ca²⁺ overload

The ECG in Digoxin Therapy vs Toxicity

Common Mistake: The "Salvador Dalí moustache" scooped ST depression is a marker of digoxin therapy (digitalis effect), not toxicity. Do not use it to diagnose or grade toxicity.

Hyperkalaemia in Acute Toxicity

Acute digoxin poisoning blocks Na⁺/K⁺-ATPase systemically → K⁺ cannot re-enter cells → hyperkalaemia.

This is a critical prognostic marker:

$$K^+ > 5.5 \, \text{mmol/L} \Rightarrow \text{mortality} \approx 50\% \text{ without antidote (historical data)}$$

• K⁺ >5.0-5.5 mmol/L in acute ingestion = indication for DigiFab (see below)
• Hyperkalaemia in chronic toxicity is less common, usually driven by renal failure
• Treat the K⁺ only by treating the toxicity (DigiFab); do not use calcium unless there is genuine cardiac arrest with no DigiFab available

Pitfall (CRITICAL): Avoid calcium for digoxin-induced hyperkalaemia. The theoretical concern is "stone heart", fixed hypercontracture of a Ca²⁺-overloaded myocardium causing refractory systole. Contemporary evidence weakens (but does not abolish) this concern. However, DigiFab is the definitive treatment; calcium risks delaying it and may worsen intracellular Ca²⁺ overload. If calcium is unavoidable (imminent cardiac arrest, no DigiFab), use it, but prioritise DigiFab.

Precipitants and Drug Interactions

Why Toxicity Occurs

Most ICU digoxin toxicity is chronic/cumulative rather than acute massive overdose. Common precipitants:

Pitfall: Amiodarone is the most clinically important interaction. Starting amiodarone in a digoxin-maintained patient without halving the digoxin dose is a common cause of iatrogenic toxicity.

Diagnosis and Risk Stratification

Clinical Features

Cardiac: Any arrhythmia (see above); haemodynamic instability in severe toxicity.

Non-cardiac (early warning signs, often precede arrhythmia):

• Nausea, vomiting, anorexia
• Visual disturbances, xanthopsia (yellow-green haloes), blurred vision
• Confusion, weakness, lethargy

Investigations

• Serum digoxin level: at ≥6 hours post-ingestion for acute; trough (pre-dose) for chronic monitoring
• 12-lead ECG: essential; serial monitoring
• Electrolytes (K⁺, Mg²⁺, Ca²⁺), direct prognostic and therapeutic relevance
• Renal function (eGFR/creatinine), determines ongoing clearance
• Thyroid function if chronic toxicity without obvious precipitant

Risk Stratification for Acute Ingestion

DigiFab (Digoxin-Specific Antibody Fragments)

Mechanism

• DigiFab consists of Fab fragments of sheep-derived digoxin-specific antibodies.
• Each vial contains 40 mg of purified Fab fragments, which bind free digoxin with high affinity, rapidly removing it from Na/K-ATPase receptors.
• The digoxin-Fab complex is renally excreted (though this is slow; elimination still occurs by redistribution from tissues first).
• Each vial binds approximately 0.5 mg digoxin
• Onset of effect: within 30 minutes (often faster, visible arrhythmia resolution)
• After administration, total serum digoxin level rises (measures bound + free), free digoxin level is the only valid measure, but this is not routinely available; levels are unreliable for 5-7 days post-DigiFab

Indications for DigiFab

Acute ingestion, administer DigiFab if ANY of:

• Life-threatening arrhythmia (high-degree AV block, VT, VF, haemodynamic compromise)
• Ingestion >10 mg (adult) or >4 mg (child)
• Serum digoxin >15 ng/mL (at equilibrium, ≥6 hours post-ingestion)
• K⁺ >5.0-5.5 mmol/L in context of acute digoxin toxicity

Chronic toxicity, administer DigiFab if:

• Life-threatening arrhythmia
• K⁺ >6.0 mmol/L (more conservative threshold in chronic toxicity, where K⁺ elevation often reflects renal failure rather than pump blockade alone)
• Haemodynamic instability
• Significant end-organ dysfunction from toxicity

Special considerations:

• Yellow oleander and foxglove co-ingestion, cross-react with digoxin assay and respond to DigiFab; empiric dosing warranted
• Cardiac glycoside-containing plants (bufo toad venom, chansu, oleander), variable cross-reactivity; DigiFab often still effective

Dosing, DigiFab

Three approaches based on available clinical information:

1. Known serum level + weight (most precise):

$$\text{Vials} = \frac{\text{Digoxin level (ng/mL)} \times \text{Weight (kg)}}{100}$$

Example: Digoxin 4 ng/mL, 70 kg patient: $$= \frac{4 \times 70}{100} = 2.8 \Rightarrow \text{round up to 3 vials}$$

2. Known amount ingested:

$$\text{Vials} = \frac{\text{mg ingested} \times 0.8}{0.5}$$

Bioavailability correction 0.8 (oral); each vial binds 0.5 mg.

Example: 5 mg ingested: $$= \frac{5 \times 0.8}{0.5} = 8 \text{ vials}$$

3. Empiric dosing (unknown amount, life-threatening toxicity):

Administration

• Reconstitute each 40 mg vial in 4 mL sterile water → dilute in 100 mL sodium chloride 0.9%
• Administer over 30 minutes (bolus in cardiac arrest)
• Monitor for: anaphylaxis (rare, sheep protein; pre-treatment with antihistamine if time permits), hypomagnesaemia, hypokalaemia post-treatment (as K⁺ re-enters cells), worsening heart failure (loss of digoxin's inotropic support, significant in those dependent on it)

Post-DigiFab Monitoring

• Serum digoxin levels invalid for 5-7 days (assay detects total digoxin including Fab-bound)
• Rebound toxicity: possible as Fab-digoxin complexes are eliminated and tissue digoxin redistributes; monitor ECG for 12-24 hours (longer in renal failure)
• Electrolytes: K⁺ and Mg²⁺ may fall rapidly as pump function resumes; replace proactively
• Renal failure: Fab-digoxin complexes accumulate; prolonged monitoring for rebound

Management of Specific Complications

Bradycardia / AV Block

1. Atropine 0.6 mg IV (up to 3 mg total), first line, restores vagal blockade
2. Transvenous cardiac pacing: if atropine fails; pacing threshold may be elevated in digoxin toxicity, use higher outputs
3. DigiFab: definitive; if haemodynamically significant, administer concurrently with pacing

Pitfall: Isoprenaline can precipitate ventricular arrhythmias in digoxin toxicity, avoid or use with extreme caution.

Ventricular Tachyarrhythmias

• DigiFab first: most digoxin VT responds within 30 minutes
• Magnesium sulfate 2-4 g IV over 15-20 minutes, particularly for digoxin-induced torsades de pointes (can occur despite QT not being prolonged); also stabilises membranes
• Lidocaine: acceptable alternative for VT if DigiFab not immediately available (does not worsen AV conduction)
• Phenytoin: historical use for digoxin VT; rarely used now; can decrease AV block

Cardioversion paradox:

External cardioversion in digoxin toxicity carries risk of precipitating refractory VF. Reserve for haemodynamically unstable VT/VF only. Use the lowest effective energy, under sedation cover, after DigiFab administration if possible.

Hyperkalaemia

• Kayexalate / resonium: too slow; not appropriate acutely
• Haemodialysis: not effective for digoxin removal (large Vd) but may help K⁺ management
• Calcium: use only as last resort (see pitfall above); if used, can give calcium gluconate 10 mL 10% IV

Electrolyte Correction

• Hypokalaemia: replete aggressively (target K⁺ >4.0 mmol/L); hypokalaemia sensitises to digoxin toxicity and worsens arrhythmias
• Hypomagnesaemia: replete with magnesium sulfate; often co-exists with hypokalaemia and promotes digoxin toxicity
• Hypercalcaemia: treat underlying cause; avoid further calcium supplementation

Disposition and Adjuncts

Gastrointestinal Decontamination

• Activated charcoal (50 g single dose) within 1-2 hours of ingestion if airway protected and no bowel obstruction
• Multiple-dose activated charcoal (MDAC): interrupts enterohepatic circulation; reduces t½; consider in significant ingestion (50 g 4-hourly, 3-4 doses)
• Cholestyramine: historical; not routinely recommended

Dialysis and Haemoperfusion

• Not effective for digoxin removal due to large Vd (5-10 L/kg)
• Haemodialysis may be used to manage renal failure and electrolyte disturbances as adjuncts

Key Numbers Summary

ICU Relevance

Monitoring

• Continuous cardiac monitoring: for any suspected digoxin toxicity; arrhythmias can be sudden and fatal
• 12-lead ECG: serial; assess for evolving AV block, VT, bidirectional VT
• Electrolytes (K⁺, Mg²⁺, Ca²⁺), 4-hourly minimum in acute toxicity; post-DigiFab hypokalaemia is common and can trigger new arrhythmias
• Renal function: daily; drives clearance and rebound risk
• Digoxin levels: post-DigiFab, total digoxin levels are not interpretable; clinical endpoints guide management

Common ICU Scenarios

1. Chronic digoxin toxicity with AKI: most common ICU presentation; renal failure causes accumulation; treat precipitant, hold digoxin, low-dose DigiFab for arrhythmia
2. Amiodarone-digoxin interaction: patient admitted for AF management started on amiodarone, develops complete heart block on digoxin; DigiFab + pacing
3. Acute overdose: intentional or accidental; large Vd means dialysis unhelpful; DigiFab, MDAC, supportive care
4. Plant-related cardiac glycoside poisoning: yellow oleander is relevant in South/Southeast Asian patient populations presenting to Australian hospitals; cross-reacts with digoxin assay; DigiFab indicated empirically

Escalation Triggers

• Haemodynamic instability → DigiFab + transvenous pacing team
• K⁺ >5.0 mmol/L rising → DigiFab now; contact pharmacy for vials
• Bidirectional VT → DigiFab bolus; avoid cardioversion until DigiFab given
• Rebound arrhythmia post-DigiFab → repeat dose; prolonged monitoring in renal failure

Pitfalls Summary

1. Don't give calcium for digoxin-toxic hyperkalaemia, give DigiFab.
2. Don't cardiovert until DigiFab is on board, precipitates refractory VF.
3. Don't trust digoxin levels for 5-7 days post-DigiFab, clinical endpoints only.
4. Don't forget amiodarone halves the digoxin dose requirement, failure to adjust causes toxicity.
5. Don't draw levels <6 hours post-ingestion, unreliable pre-equilibration.
6. Do replete K⁺ and Mg²⁺ aggressively, both sensitise to digoxin toxicity and worsen arrhythmias.
7. Do monitor for hypokalaemia post-DigiFab, as pump function restores, K⁺ re-enters cells rapidly.